Debt-free Balance SheetA zero-debt capital structure gives the company durable financial flexibility to fund R&D, regulatory work, or commercialization without immediate interest burdens. Over a 2–6 month horizon this lowers default risk and preserves options to raise non-debt capital or execute strategic investments as needed.

Sharp Revenue Scaling With Solid Gross MarginRapid top-line growth coupled with a ~52% gross margin signals underlying commercial traction and reasonable unit economics. If revenue growth persists, the company can leverage margins to improve operating leverage, making a path to positive operating cash flow more attainable over the medium term.

Lean Workforce Supports Capital EfficiencyA compact headcount implies a relatively low fixed-cost base and the potential to scale revenue without proportionate payroll increases. Over several months this can help stretch limited cash reserves and allow management to prioritize spend on high-impact commercialization or R&D activities.

Bears Say

High Cash Burn And Negative Free Cash FlowConsistently large negative operating and free cash flows indicate the business is consuming cash faster than it generates it. This persistent burn requires external funding or equity raises, which can dilute existing holders and constrain strategic flexibility over the next several months if corrective actions are not taken.

Large Operating And Net LossesSubstantial operating and net losses show the company has not yet achieved operating breakeven despite revenue growth. Enduring losses pressure cash runway and mean management must materially improve margins or secure financing, both of which are structural challenges that affect sustainability over 2–6 months.

Negative Returns On EquityA negative ROE indicates the company is destroying shareholder capital rather than generating returns. Even with no debt, ongoing losses diluted by an equity-funded balance sheet risk further shareholder dilution and reduced capital efficiency if profitability is not achieved within the medium term.

4894 FAQ

What was Cuorips Inc.’s price range in the past 12 months?

Cuorips Inc. lowest stock price was ¥5580.00 and its highest was ¥12400.00 in the past 12 months.

What is Cuorips Inc.’s market cap?

Cuorips Inc.’s market cap is ¥58.51B.

When is Cuorips Inc.’s upcoming earnings report date?

Cuorips Inc.’s upcoming earnings report date is May 20, 2026 which is in 71 days.

How were Cuorips Inc.’s earnings last quarter?

Cuorips Inc. released its earnings results on Feb 18, 2026. The company reported -¥30.15 earnings per share for the quarter, missing the consensus estimate of N/A by -¥30.15.

Is Cuorips Inc. overvalued?

According to Wall Street analysts Cuorips Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cuorips Inc. pay dividends?

Cuorips Inc. does not currently pay dividends.

What is Cuorips Inc.’s EPS estimate?

Cuorips Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cuorips Inc. have?

Cuorips Inc. has 8,268,076 shares outstanding.

What happened to Cuorips Inc.’s price movement after its last earnings report?

Cuorips Inc. reported an EPS of -¥30.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.324%.

Which hedge fund is a major shareholder of Cuorips Inc.?

Currently, no hedge funds are holding shares in JP:4894

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cuorips Inc.

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.